Tough guidelines proposed for genetic breast cancer test
This article was originally published in Clinica
An ethics panel in the US has called for strict guidelines to ensure that genetic tests for breast cancer are only used on patients who will benefit from the information they provide. Testing for BRCA1 and BRCA2 mutations should not be used on most women and marketing of these tests should be strictly limited, the panel said.
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.